180 related articles for article (PubMed ID: 37385569)
1. Identification of integrase inhibitor-related drug resistance mutations in newly diagnosed ART-naïve HIV patients.
Wang N; Xiong X; Liu Z; Zhang R; Luo S; Zhang H; Wu X
Microb Pathog; 2023 Aug; 181():106217. PubMed ID: 37385569
[TBL] [Abstract][Full Text] [Related]
2. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
3. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
4. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors.
Borghetti A; Ciccullo A; Lombardi F; Baldin G; Belmonti S; Prosperi M; Incardona F; Heger E; Borghi V; Sönnerborg A; Zazzi M; De Luca A; Di Giambenedetto S
HIV Med; 2021 Jan; 22(1):22-27. PubMed ID: 32964671
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).
Yang Z; Yang X; Deng X; Wei S; Liu J; Ma J; Zhao Q; Huo Y
Infection; 2021 Dec; 49(6):1195-1202. PubMed ID: 34279816
[TBL] [Abstract][Full Text] [Related]
6. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary.
Áy É; Pocskay Á; Lakatos B; Szlávik J; Mezei M; Minárovits J
Acta Microbiol Immunol Hung; 2021 Jun; 68(2):87-91. PubMed ID: 34125695
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
9. Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.
Lai J; Liu Y; Han X; Huang A; Lin J; Ao W; Ye H; Chen Y
Drug Des Devel Ther; 2021; 15():889-894. PubMed ID: 33679129
[TBL] [Abstract][Full Text] [Related]
10. Increased prevalence of pretreatment drug resistance mutations in treatment-naïve people living with HIV-1 in Henan Province, China (2022/23).
Liu J; Liu C; Wang Y; Wei S; Ma J; Li Y; Chen X; Zhao Q; Huo Y
Infect Genet Evol; 2023 Nov; 115():105520. PubMed ID: 37898414
[TBL] [Abstract][Full Text] [Related]
11. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.
Tostevin A; White E; Dunn D; Croxford S; Delpech V; Williams I; Asboe D; Pozniak A; Churchill D; Geretti AM; Pillay D; Sabin C; Leigh-Brown A; Smit E;
HIV Med; 2017 Mar; 18(3):204-213. PubMed ID: 27476929
[TBL] [Abstract][Full Text] [Related]
12. Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains.
Chrysostomou AC; Topcu C; Stylianou DC; Hezka J; Kostrikis LG
Infect Genet Evol; 2020 Jul; 81():104243. PubMed ID: 32061896
[TBL] [Abstract][Full Text] [Related]
13. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Margot NA; Wong P; Kulkarni R; White K; Porter D; Abram ME; Callebaut C; Miller MD
J Infect Dis; 2017 Mar; 215(6):920-927. PubMed ID: 28453836
[TBL] [Abstract][Full Text] [Related]
14. Primary resistance to integrase inhibitors in Shenzhen.
Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
[TBL] [Abstract][Full Text] [Related]
15. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
Kleinmann WN; Pruszynski JE; Adhikari EH
Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
[TBL] [Abstract][Full Text] [Related]
16. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
18. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
19. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
